American Association of Acupuncture and Oriental Medicine

We serve to advance the profession and practice of AOM

The statements and opinions contained in the articles on the American Association of Acupuncture and Oriental Medicine's (AAAOM) Blog are solely those of the individual authors and contributors and not of the AAAOM. The appearance of advertisements in the AAAOM’s publications are not a warranty, endorsement or approval of the products or their safety. The AAAOM disclaims responsibility for any loss, injury or damage to persons or property resulting from any ideas or products referred to in any article or advertisement. Readers are advised to verify any information on which they choose to rely. 


Efficacy and Tolerability of FuFang DanShen as Add-On Antihypertensive Therapy

06 Sep 2016 2:45 PM | AAAOM Admin (Administrator)

THE EFFICACY AND TOLERABILITY OF FUFANG DANSHEN (SALVIA MILTIORRHIZA) AS ADD-ON ANTIHYPERTENSIVE THERAPY IN TAIWANESE PATIENTS WITH UNCONTROLLED HYPERTENSION.

Posted By Al Stone, Saturday, May 05, 2012

Phytother Res. 2012 Feb;26(2):291-8. doi: 10.1002/ptr.3548. Epub 2011 Sep 2.

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF FUFANG DANSHEN (SALVIA MILTIORRHIZA) AS ADD-ON ANTIHYPERTENSIVE THERAPY IN TAIWANESE PATIENTS WITH UNCONTROLLED HYPERTENSION.


Yang TYWei JCLee MYChen CMUeng KC.

SOURCE

Department of Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

ABSTRACT

Hypertension generally requires the use of a combination therapy to achieve the satisfactory control of blood pressure. A traditional Chinese herb, Danshen (Salvia miltiorrhiza), has been shown to have cardioprotective effects in animals and humans. The study investigated the add-on effect of Fufang Danshen extract capsule in Taiwanese hypertensive patients with uncontrolled blood pressure. This was a double-blind, placebo-controlled, randomized, single-center study clinical trial. Fifty-five patients with uncontrolled mild to moderate hypertension were enrolled under current conventional antihypertensive treatment, randomized equally to receive a Fufang Danshen capsule (formula mixture) 1000 mg twice-daily or a placebo capsule for 12 weeks. Primary endpoints were the control rate and the response rate. By ITT analysis at week 12, the control rates were 25.5% in the Fufang Danshen group and 7.3% in the control group (p = 0.016). The response rates were 45.6% in the Fufang Danshen group and 38.2% in the placebo group (p = 0.946). A significant reduction of systolic blood pressure at week 12 was noted in the Fufang Danshen group compared with the placebo group (13.8 vs 4.2 mmHg, p = 0.005). A decrease of pulse rate was also noted in the Fufang Danshen group (- 3.2 vs +2.7/min, p = 0.027). Adverse events were not statistically different between the two groups. It was concluded that Fufang Danshen (Salvia miltiorrhiza) extract reduced systolic blood pressure and pulse rate, and was well tolerated in patients with hypertension.

Copyright © 2011 John Wiley & Sons, Ltd.

PMID: 21887804 [PubMed - indexed for MEDLINE]

Tags:  dan shen  high blood pressure  hypertension  research  salvia 



   acupuncture website design                                                                     

                                                                                                                 
                      
   


PO Box 96503 #44114, Washington DC 20090-6503

Reach us at admin@aaaomonline.org

Powered by Wild Apricot Membership Software